New cancer drugs "vastly overestimated", says contrarian analyst

LONDON, March 31 (Reuters) - A hot new class of drugs designed to help the body's own immune system fend off cancer by blocking a protein called PD-1 is going to be big - but not nearly as big as investors think, according to a new analysis.